Advertisement
Screener

Amylyx Pharmaceuticals, Inc. (AMLX) Cash Flow Breakdown

Amylyx Pharmaceuticals, Inc. Cash Flow Breakdown

Cash flow breakdown shows where Amylyx Pharmaceuticals, Inc.'s cash came from and where it went: from running the business, from investing (buying or selling equipment, companies and investments) and from financing (borrowing, paying back loans, buying back shares, paying dividends). One row per year or quarter. A minus sign means cash went out. Financing is shown line by line: buybacks, dividends, debt paid back, new debt and the rest. All amounts are the filed figures for that period.

  • Fiscal year ended 2025-12-31: from running the business, $123.34M went out.
  • Fiscal year ended 2025-12-31: from investing, $14.04M came in.
  • Fiscal year ended 2025-12-31: from financing, $257.03M came in.
  • Fiscal year ended 2025-12-31: change in cash, $148.80M came in.

A minus sign means cash went out. * = worked out from the filed year-to-date figures (hover to see how); greyed = already counted inside another line.

Each year (12 month)

Fiscal year endRunning the businessFrom investingNew shares soldNot split outChange in cash
2025-12-31-$123.34M$14.04M$257.03M*$148.80M
2024-12-31-$167.65M$75.65M-$92.08M
2023-12-31$11.92M$92.05M$6.99M-$3.45M*$107.67M
2022-12-31-$179.87M-$238.99M$2.19M$429.60M*$12.87M
2021-12-31-$74.80M-$46.41M$343.00K$158.16M*$37.31M

Each quarter (3 month)

Quarter endRunning the businessFrom investingNew shares soldNot split outChange in cash
2026-06-30-$31.42M*-$149.80M*$1.48M*
2026-03-31-$36.88M$36.26M$3.22M*$2.49M
2025-12-31-$27.90M*$29.47M*
2025-09-30-$30.37M*$5.24M*$191.61M*
2025-06-30-$25.25M*$22.99M*
2025-03-31-$39.82M-$43.66M$65.66M*-$17.62M
2024-12-31-$59.01M*$64.98M*
2024-09-30-$41.57M*$38.82M*
2024-06-30-$66.58M*-$28.96M*
2024-03-31-$489.00K$819.00K$351.00K
2023-12-31$13.55M*$20.93M*$347.00K*
2023-09-30-$5.17M*-$108.09M*$984.00K*
2023-06-30$8.61M*$123.22M*$2.12M*-$740.00K*
2023-03-31-$5.07M$55.99M$1.04M*$52.04M
2022-12-31-$49.70M*-$228.18M*$1.94M*$230.22M*
2022-09-30-$43.08M*$84.04M*$0.00*
2022-06-30-$46.46M*$4.46M*-$828.00K*
2022-03-31-$40.63M-$99.31M$200.46M*$60.44M
2021-12-31-$28.24M*$2.81M*$145.00K*-$1.21M*
2021-09-30-$20.86M*-$49.21M*$164.00K*$131.49M*
2021-06-30-$13.05M*$0.00*$3.00K*$1.99M*
2021-03-31-$12.64M-$14.00K$31.00K$25.90M*$13.27M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Enliven Therapeutics, Inc. (ELVN)United States$3.307B-35.07
Arcutis Biotherapeutics, Inc. (ARQT)United States$3.303B115.47
Arcus Biosciences, Inc. (RCUS)United States$3.188B-8.52
IDEAYA Biosciences, Inc. (IDYA)United States$3.540B-20.52
Organon & Co. (OGN)United States$3.603B17.03
Dyne Therapeutics, Inc. (DYN)United States$3.084B-7.09
Xenon Pharmaceuticals Inc. (XENE)$3.684B-14.27
ACADIA PHARMACEUTICALS INC (ACAD)United States$3.823B11.45
AbCellera Biologics Inc. (ABCL)$3.879B-14.59
PRECIGEN, INC. (PGEN)United States$2.757B-12.94